Form 4 for HAE HAEMONETICS CORP
Accepted 2024-05-21 00:00:00 ET · period of report 2024-05-17 · accession 0001127602-24-016175 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-05-21 | 2024-05-17+ | HAE | Strong Stewart W | Pres, Gbl Hospital | F - Tax | $95.18 | -1,839 | 15.3K | -11% | -$175.0K |
| D | 2024-05-21 | 2024-05-20 | HAE | Strong Stewart W | Pres, Gbl Hospital | S - Sale+OE | $95.11 | -686 | 18.2K | -4% | -$65.2K |
| D | 2024-05-21 | 2024-05-20 | HAE | Strong Stewart W | Pres, Gbl Hospital | M - OptEx | $56.57 | +2,241 | 20.4K | +12% | +$126.8K |
| D | 2024-05-21 | 2024-05-17 | HAE | Strong Stewart W | Pres, Gbl Hospital | A - Grant | — | +2,872 | 18.2K | +19% | — |
| D | 2024-05-21 | 2024-05-17 | HAE | Strong Stewart W | Pres, Gbl Hospital | A - Grant | $0.00 | +6,313 | 6,313 | New | $0 |
| D | 2024-05-21 | 2024-05-20 | HAE | Strong Stewart W | Pres, Gbl Hospital | M - OptEx | $0.00 | -2,241 | 2,242 | -50% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-05-20 | F | D | 1,555 | $95.08 | 18,882 | D | — | — | (F6) Represents shares withheld for tax obligations and for payment of the exercise price on exercised stock options reported in Table I. (F2) This number includes unvested RSUs previously reported. |
| 2 | Common | Common Stock | 2024-05-20 | S | D | 686 | $95.11 | 18,196 | D | — | — | (F2) This number includes unvested RSUs previously reported. |
| 3 | Common | Common Stock | 2024-05-20 | M | A | 2,241 | $56.57 | 20,437 | D | — | — | (F2) This number includes unvested RSUs previously reported. |
| 4 | Common | Common Stock | 2024-05-17 | A | A | 2,872 | — | 18,196 | D | — | — | (F3) The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant. (F4) Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. (F2) This number includes unvested RSUs previously reported. |
| 5 | Common | Common Stock | 2024-05-17 | F | D | 284 | $95.73 | 15,324 | D | — | — | (F1) Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. (F2) This number includes unvested RSUs previously reported. |
| 6 | Derivative | Non-qualified Stock Option (Right to Buy) | 2024-05-17 | A | A | 6,313 | $0.00 | 6,313 | D | $95.73 · — to 2031-05-17 | 6,313 Common Stock | (F7) Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. |
| 7 | Derivative | Non-qualified Stock Option (Right to Buy) | 2024-05-20 | M | D | 2,241 | $0.00 | 2,242 | D | $56.57 · 2023-05-18 to 2028-05-18 | 2,241 Common Stock | (F8) Reflects options granted on May 18, 2021 that vest in annual increments of 25% beginning on the first anniversary of the date of grant. |